Portefeuille d'ETF SCHB (NYSE) - Page 115 | MetaTrader

Afficher le graphique complet

Aperçu Toutes les participations Heatmap

Principaux titres en portefeuille Market Value Shares Weight %

ENTA Enanta Pharmaceuticals Inc 155.5697 K 10.8790 K 0.0004%

BH Biglari Holdings Inc 155.1120 K 400.0000 0.0004%

VIA Via Transportation Inc 154.6200 K 9 000.0000 0.0004%

MGPI MGP Ingredients Inc 154.5080 K 8 132.0000 0.0004%

HYLN Hyliion Holdings Corp 151.4806 K 73.8930 K 0.0004%

LUCK Lucky Strike Entertainment Corp 151.4719 K 18.0970 K 0.0004%

CHRS Coherus Oncology Inc 150.7325 K 90.2590 K 0.0004%

SMRT SMARTRENT INC 150.5226 K 99.0280 K 0.0004%

HLLY Holley Inc 150.4786 K 36.8820 K 0.0004%

EVEX Eve Holding Inc 150.3420 K 50.1140 K 0.0004%

RZLT Rezolute Inc 148.7899 K 46.3520 K 0.0004%

DDD 3D Systems Corp 148.4209 K 76.9020 K 0.0004%

GYRE Gyre Therapeutics Inc 148.3200 K 18.0000 K 0.0004%

CRBU Caribou Biosciences Inc 148.2722 K 78.0380 K 0.0004%

SNBR Sleep Number Corp 148.0800 K 24.0000 K 0.0004%

NRC National Research Corp 147.5100 K 11.0000 K 0.0004%

RMR RMR Group Inc/The 147.4200 K 9 000.0000 0.0004%

ORGO Organogenesis Holdings Inc 147.3904 K 45.9160 K 0.0004%

CLW Clearwater Paper Corp 147.2917 K 9 826.0000 0.0004%

BRCB Black Rock Coffee Bar Inc 146.7133 K 10.9980 K 0.0004%

Nouvelles

SCHB: SCHB: A Hold Amid Premium Valuations And Higher Risk-Free Rates (NYSEARCA:SCHB)

Large Caps - Big Opportunity

3 Reasons Why I Remain Bullish On SCHB, And 2 To Sell It Immediately (NYSEARCA:SCHB)

Q1 2026 Dividend Check-In: Highest Quarterly Hike Percentage Since 2019

Big Tech's $635B AI Push Meets Energy Crunch: ETFs to Diversify

Patience Pays: ETFs You Can Buy and Hold for the Long Run

3 Best ETFs to Invest In, According to AI Analyst, 2/5/2026 - TipRanks.com

SCHB: The Conflict Between Short- And Long-Term Risks (NYSEARCA:SCHB)

ETFs to Keep Your Portfolio on Track in the Long Term

SCHB: Core Equity Holding For Diversified Investors (NYSEARCA:SCHB)

Capital Markets Outlook Q4 2025: Kicking The Can Down The Tightrope

Equity Outlook: From Caution To Complacency?